EGFR and breast carcinoma: Despite the fact that EGFRIs have significant clinical outcomes in treating patients with breast cancer, tumor cells rapidly develop acquired resistance, in which the efficacy of EGFR-targeted therapy is highly limited16 (Fig. 1).